Researchers are leveraging artificial intelligence to revolutionize protein modeling and cellular behavior predictions, significantly accelerating drug discovery. Microsoft Research has unveiled BioEmu, a generative deep learning system capable of rapidly simulating protein equilibrium ensembles with high accuracy, outperforming traditional molecular dynamics simulations. Meanwhile, Columbia University and the Chan Zuckerberg Initiative developed GREmLN, an AI model employing graph-based architectures to capture complex gene regulatory networks, aiding in understanding cell state transitions in health and disease. These advanced AI tools, by enabling high-throughput and precise modeling, promise to greatly enhance target identification and therapeutic development efficiency.